Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease

Ivana Hollan, Barbara Bottazzi, Ivan Cuccovillo, Øystein T. Førre, Knut Mikkelsen, Kjell Saatvedt, Sven Martin Almdahl, Alberto Mantovani, Pier Luigi Meroni

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective. Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls. Methods. We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. Results. The mean ± SD serum PTX3 level in the CAD/IRD group was 1.96 ± 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 ± 0.74 ng/ml) and healthy control (1.21 ± 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. Conclusion. CAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.

Original languageEnglish
Pages (from-to)378-385
Number of pages8
JournalArthritis Care and Research
Volume62
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Rheumatic Diseases
Biomarkers
Serum
Coronary Artery Disease
Acute Coronary Syndrome
Systemic Lupus Erythematosus
PTX3 protein
Alcohols
Connective Tissue Diseases
Innate Immunity
Coronary Artery Bypass
Cardiovascular Diseases

ASJC Scopus subject areas

  • Rheumatology

Cite this

Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. / Hollan, Ivana; Bottazzi, Barbara; Cuccovillo, Ivan; Førre, Øystein T.; Mikkelsen, Knut; Saatvedt, Kjell; Almdahl, Sven Martin; Mantovani, Alberto; Meroni, Pier Luigi.

In: Arthritis Care and Research, Vol. 62, No. 3, 03.2010, p. 378-385.

Research output: Contribution to journalArticle

Hollan, Ivana ; Bottazzi, Barbara ; Cuccovillo, Ivan ; Førre, Øystein T. ; Mikkelsen, Knut ; Saatvedt, Kjell ; Almdahl, Sven Martin ; Mantovani, Alberto ; Meroni, Pier Luigi. / Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. In: Arthritis Care and Research. 2010 ; Vol. 62, No. 3. pp. 378-385.
@article{3446d52b19144c53bbbc9de5b50551c0,
title = "Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease",
abstract = "Objective. Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls. Methods. We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. Results. The mean ± SD serum PTX3 level in the CAD/IRD group was 1.96 ± 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 ± 0.74 ng/ml) and healthy control (1.21 ± 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. Conclusion. CAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.",
author = "Ivana Hollan and Barbara Bottazzi and Ivan Cuccovillo and F{\o}rre, {{\O}ystein T.} and Knut Mikkelsen and Kjell Saatvedt and Almdahl, {Sven Martin} and Alberto Mantovani and Meroni, {Pier Luigi}",
year = "2010",
month = "3",
doi = "10.1002/acr.20094",
language = "English",
volume = "62",
pages = "378--385",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease

AU - Hollan, Ivana

AU - Bottazzi, Barbara

AU - Cuccovillo, Ivan

AU - Førre, Øystein T.

AU - Mikkelsen, Knut

AU - Saatvedt, Kjell

AU - Almdahl, Sven Martin

AU - Mantovani, Alberto

AU - Meroni, Pier Luigi

PY - 2010/3

Y1 - 2010/3

N2 - Objective. Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls. Methods. We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. Results. The mean ± SD serum PTX3 level in the CAD/IRD group was 1.96 ± 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 ± 0.74 ng/ml) and healthy control (1.21 ± 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. Conclusion. CAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.

AB - Objective. Pentraxin 3 (PTX3), a key component of innate immunity, is a strong marker of disease severity in coronary artery disease (CAD). The aim of this study was to compare levels of serum PTX3 in CAD patients with and without inflammatory rheumatic disease (IRD) and in healthy controls. Methods. We examined 69 patients with IRD (CAD/IRD group) and 53 patients without IRD (CAD/non-IRD) referred to coronary artery bypass grafting, and 30 healthy controls. Results. The mean ± SD serum PTX3 level in the CAD/IRD group was 1.96 ± 0.98 ng/ml; this was statistically significantly higher than that of the CAD/non-IRD (1.41 ± 0.74 ng/ml) and healthy control (1.21 ± 0.59 ng/ml) groups. In contrast to most other IRDs, serum PTX3 levels were relatively low in patients with systemic lupus erythematosus (SLE) and other systemic connective tissue diseases. In sex- and age-adjusted analysis, IRD, acute coronary syndromes, and low alcohol intake were associated with higher serum PTX3 levels. Conclusion. CAD patients with IRD had higher mean serum PTX3 levels than patients without IRD and healthy controls. In addition, acute coronary syndromes and low alcohol intake independently predicted higher serum PTX3 levels. Higher serum PTX3 levels in IRD may be related to the higher cardiovascular risk of IRD patients. Circulating PTX3 could likely be used as a biomarker for severity of cardiovascular disease in IRDs; its importance, however, might be limited in SLE and related disorders.

UR - http://www.scopus.com/inward/record.url?scp=77649210481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649210481&partnerID=8YFLogxK

U2 - 10.1002/acr.20094

DO - 10.1002/acr.20094

M3 - Article

VL - 62

SP - 378

EP - 385

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 3

ER -